Official Telehealth FX press releases examining daily needle-free Sublingual & Oral Semaglutide Tablets/Drops ($149/mo) and Oral Tirzepatide Rapid-Dissolve Tablets ($199/mo) compared to weekly subcutaneous injections.
Board-certified telemedicine and USP <797> 503A sterile compounding with $49/mo Semaglutide, $99/mo Tirzepatide, $0 membership fees, and free 2-day cold-chain delivery.
The telehealth-based option combines online clinician review, daily sublingual tablet use, and direct-to-door access when prescribed.
The sublingual tablet option gives eligible adults a needle-free way to explore dual GIP and GLP-1 weight loss support.
The new dissolving tablet option is designed for eligible adults who want dual-action GIP and GLP-1 support in a once-daily routine.
The once-daily sublingual tablet format gives eligible adults a new way to explore dual GIP and GLP-1 weight loss support without weekly injections.
The sublingual tablet format is designed to dissolve under the tongue and support eligible adults seeking provider-guided GLP-1 weight loss care.
The once-daily dissolving tablet option is designed for eligible adults who want a needle-free semaglutide routine with provider review.
The new dissolving tablet format offers eligible adults a convenient alternative to weekly semaglutide injections.
The once-daily dissolving tablet format gives eligible patients a new way to explore GLP-1 weight loss support without weekly injections.
The new telehealth option gives adults a convenient way to explore under-the-tongue semaglutide with provider review and needle-free administration.
The new sublingual medication format offers eligible adults a daily needle-free option for GLP-1 weight loss support.
The new daily medication format is designed for eligible adults who want to explore semaglutide support without weekly injections.
New consumer-focused resource explains how under-the-tongue semaglutide may fit into online weight loss research for adults comparing GLP-1 options.